<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the current study, we determined the functional significance of <z:chebi fb="199" ids="26708">sodium</z:chebi>-dependent/-independent <z:chebi fb="105" ids="17234">glucose</z:chebi> transporters at the neurovasculature during oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (OGD) </plain></SENT>
<SENT sid="1" pm="."><plain>Confluent brain endothelial cells cocultured with astrocytes were exposed to varying degrees of in vitro <z:hpo ids='HP_0001297'>stroke</z:hpo> conditions </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> transporter (GLUT) 1 and <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="105" ids="17234">glucose</z:chebi> cotransporter (SGLT) activity were investigated by <z:chebi fb="2" ids="8069">luminal</z:chebi> membrane uptake and transport studies using [(3)H]<z:chebi fb="0" ids="4167">D-glucose</z:chebi> and also by [(14)C]alpha-<z:chebi fb="0" ids="37657">methyl D-glucopyranoside</z:chebi> (AMG), a specific, nonmetabolized substrate of SGLT </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> experiments were tested to determine whether blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) SGLT activity was induced during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Increases in <z:chebi fb="2" ids="8069">luminal</z:chebi> <z:chebi fb="0" ids="4167">D-glucose</z:chebi> and AMG uptake and transport were observed with in vitro <z:hpo ids='HP_0001297'>stroke</z:hpo> conditions </plain></SENT>
<SENT sid="5" pm="."><plain>Specific inhibitor experiments suggest a combined role for both SGLT and GLUT1 at the <z:chebi fb="2" ids="33602">BBB</z:chebi> during OGD </plain></SENT>
<SENT sid="6" pm="."><plain>A time-dependent increase in the uptake of AMG was also seen in mice exposed to permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and this increase was sensitive to the SGLT inhibitor, <z:chebi fb="0" ids="8113">phlorizin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> and <z:hpo ids='HP_0000969'>edema</z:hpo> ratio during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> were significantly decreased by the inhibition of this transporter </plain></SENT>
<SENT sid="8" pm="."><plain>These results show that both GLUT1 and SGLT play a role at the <z:chebi fb="2" ids="33602">BBB</z:chebi> in the blood-to-brain transport of <z:chebi fb="105" ids="17234">glucose</z:chebi> during ischemic conditions, and inhibition of SGLT during <z:hpo ids='HP_0001297'>stroke</z:hpo> has the potential to improve <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
<SENT sid="9" pm="."><plain>Pharmacological modulation of this novel <z:chebi fb="2" ids="33602">BBB</z:chebi> transporter could prove to be a brain vascular target in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>